2-NBDG: Fluorescent Glucose Analog for Glucose Uptake Measurement

Executive Summary: 2-NBDG (2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose) is a water-soluble, fluorescent glucose analog that enables precise quantification of cellular glucose uptake kinetics across mammalian cell lines and tissues. The compound is taken up via glucose transporters and phosphorylated by hexokinase, resulting in intracellular retention and fluorescence, which is measurable by flow cytometry or microscopy (APExBIO). In disease models such as diabetes and epilepsy, 2-NBDG quantifies altered glucose uptake dynamics under defined experimental conditions (e.g., 10 μM, 10 min incubation). 2-NBDG is insoluble in DMSO but dissolves in water (≥17.1 mg/mL, ultrasonic) and ethanol (≥2.93 mg/mL, warming+ultrasonic), with stocks stored at -20°C for short-term use (Hong et al., 2025). Rapid uptake kinetics and plateau phases are cell-type dependent, and the tool's specificity for glucose transporters underpins its wide research utility.

Biological Rationale

Glucose uptake is fundamental to cellular metabolism, disease progression, and therapeutic response. Quantifying this uptake informs on insulin sensitivity, cancer metabolism, and neuronal activity. Traditional radiolabeled tracers, while sensitive, require special handling and disposal procedures. 2-NBDG offers a non-radioactive, fluorescence-based alternative for tracking glucose analog transport in living systems. Its NBD (7-nitrobenz-2-oxa-1,3-diazol-4-yl) label enables detection with standard FITC/GFP filter sets, supporting multi-modal analyses such as flow cytometry, fluorescence microscopy, and high-throughput plate assays (MoleculeProbes). Studies reveal that altered glucose uptake is a hallmark of diabetes, cancer, and neurological disorders, highlighting the need for robust, scalable assays (Hong et al., 2025).

Mechanism of Action of 2-NBDG

2-NBDG is structurally derived from 2-deoxyglucose, a known substrate for facilitative glucose transporters (GLUTs). Upon exposure, 2-NBDG enters cells via these transporters, mirroring physiological glucose import (APExBIO). Once inside, hexokinase phosphorylates 2-NBDG, yielding a charged, membrane-impermeant product that accumulates intracellularly. The NBD fluorophore emits green fluorescence (excitation 465–488 nm, emission 540–550 nm), detectable with standard laboratory equipment. This mechanism ensures that signal intensity is directly proportional to glucose transporter activity and cell membrane integrity, under matched substrate concentrations and incubation times. The specificity of 2-NBDG for GLUT-mediated transport has been validated in multiple cell types, including HepG2, L6, and MCF-7 lines (MoleculeProbes).

Evidence & Benchmarks

• 2-NBDG uptake is rapid: in MCF-7 cells, maximal signal is reached within 20–30 min, with >80% plateau at 10 μM, 37°C (Hong et al., 2025).
• In BNL CL.2 hepatocytes, 2-NBDG fluorescence directly correlates with PI3K/AKT/GSK3β pathway activation and increased glucose uptake upon quercetin treatment (Hong et al., 2025).
• In animal models (Sprague–Dawley rats), 2-NBDG can localize epileptic foci and map metabolic asymmetries in brain tissue after systemic injection (MoleculeProbes).
• 2-NBDG outperforms radiolabeled 2-deoxyglucose in terms of operational safety and compatibility with live-cell imaging (Cy5 NHS-Ester).
• The B6035 kit from APExBIO provides verified solubility parameters and storage guidelines, enabling reproducible preparation for cell-based and animal assays (APExBIO).

Applications, Limits & Misconceptions

2-NBDG is applied in diverse research domains:

• Metabolic profiling of cancer cell lines (e.g., MCF-7, HepG2) to assess glycolytic reprogramming.
• Monitoring insulin sensitivity and glucose uptake in diabetes models, including high-fat diet mouse models and cell cultures (Hong et al., 2025).
• Mapping glucose metabolism in neurological tissues, such as epileptic rat brains (MoleculeProbes).
• High-content screening for modulators of glucose transporter activity.

Common Pitfalls or Misconceptions

• 2-NBDG is not metabolized beyond the first phosphorylation step; it does not report on downstream glycolytic flux.
• The compound is insoluble in DMSO; attempts to prepare DMSO stocks result in precipitation (APExBIO).
• Prolonged storage of aqueous or ethanol solutions (>1 week at 4°C) can lead to degradation; always prepare fresh working stocks.
• 2-NBDG signal may be confounded by autofluorescence in highly pigmented or necrotic tissues; include proper controls.
• Not suitable for direct measurement of glucose oxidation or ATP production.

This article extends the guidance in "Enhancing Glucose Uptake Assays: Practical Guidance with 2-NBDG" by providing updated evidence for animal models and clarifying solubility/storage best practices. It also complements "2-NBDG: A Fluorescent Glucose Analog for Glucose Uptake Measurement" by emphasizing specific disease-model applications and troubleshooting workflows.

Workflow Integration & Parameters

For optimal performance, dissolve 2-NBDG in water (≥17.1 mg/mL, ultrasonic agitation) or ethanol (≥2.93 mg/mL, 37°C plus ultrasonic). Recommended working concentrations are 10 μM for 10 min at 37°C in standard glucose-free buffer. Uptake kinetics should be validated for each cell type; for example, in MCF-7 cells, plateau is reached by 20–30 min. Use FITC-compatible filter sets for detection. For animal studies, dosing and detection parameters must be optimized according to system and tissue type. Store powder at -20°C; avoid repeated freeze-thawing of solutions.

Conclusion & Outlook

2-NBDG, as provided by APExBIO, is a validated, non-radioactive cellular glucose uptake tracer that enables real-time, quantitative monitoring of glucose transporter activity in basic and translational research. Its compatibility with diverse detection modalities and disease models, combined with well-defined handling parameters, underpins its status as a standard tool for metabolic research. Ongoing studies will further refine its applications in precision medicine, including live animal imaging and automated high-content screening (Hong et al., 2025).